We are live on ! Find out more
XENE icon

Xenon Pharmaceuticals

206 hedge funds and large institutions have $2.57B invested in Xenon Pharmaceuticals in 2025 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 68 increasing their positions, 73 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

114% more call options, than puts

Call options by funds: $14.8M | Put options by funds: $6.93M

8% more funds holding in top 10

Funds holding in top 10: 13 → 14 (+1)

6% more capital inflows, than outflows

Capital inflows: $252M | Capital outflows: $237M

0.14% more ownership

Funds ownership: 100.01% → 100.15% (+0.14%)

7% less repeat investments, than reductions

Existing positions increased: 68 | Existing positions reduced: 73

1% less funds holding

Funds holding: 209 → 206 (-3)

13% less first-time investments, than exits

New positions opened: 20 | Existing positions closed: 23

Holders
206
Holders Change
-3
Holders Change %
-1.44%
% of All Funds
2.75%
Holding in Top 10
14
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+7.69%
% of All Funds
0.19%
New
20
Increased
68
Reduced
73
Closed
23
Calls
$14.8​M
Puts
$6.93​M
Net Calls
+$7.9​M
Net Calls Change
+$3.62​M

XENE Hedge Fund Activity: Q1 2025 in Review

206 of the 7,490 institutional investors tracked by Wall St. Rank reported a position in Xenon Pharmaceuticals (XENE) for Q1 2025, worth a combined $2.57B — down 14% from $2.99B a quarter earlier.

Sellers outnumbered buyers: 23 funds closed out of XENE and 20 opened new positions — a net loss of 3 holders — while 73 trimmed existing stakes and 68 added.

The largest buyer was Deep Track Capital, adding an estimated $31.5M. The largest seller was Baker Bros. Advisors, cutting an estimated $24.5M.

  • 206 institutional investors held Xenon Pharmaceuticals (XENE) as of Q1 2025, down from 209 in Q4 2024.
  • Funds reported $2.57B of Xenon Pharmaceuticals stock for Q1 2025, down 14% quarter-over-quarter.
  • 20 funds opened new Xenon Pharmaceuticals positions in Q1 2025 and 23 closed out, a net change of -3 holders.
  • The largest Xenon Pharmaceuticals buyer in Q1 2025 was Deep Track Capital, an estimated $31.5M added.
  • The largest Xenon Pharmaceuticals seller in Q1 2025 was Baker Bros. Advisors, an estimated $24.5M sold.

Based on aggregated 13F filings for Q1 2025.